a timeline of artificial intelligence in biomedicine h/t Amee Kapadia

Introducing Signal, the new voice of next generation biotech. A few words from me on what it is and why it matters.

Herding in the drug development pipeline go.nature.com/445Tc9v This new article analyses the extent of herding around popular targets such as PD1/PDL1, CD19 and HER2 by assessing the number of assets in development for the most popular targets and indications over time

You know that magical feeling when you find the perfect music for thoughts to flow? Just found my fave new work artists+jams 🤌🏼 youtu.be/51AdXWOT0zo

Happy Friday! Reflecting this AM on many learnings as a 1st time biotech founder - no prev experience (or tweet thread for that matter) truly prepares you for the journey! but here's a few un-intuitive learnings I would've loved to have known at the beginning -->

I've updated my list of recommended resources to learn about and keep up to date with the biotech industry. I want this to be the most useful aggregation of relevant resources on the internet, anything I'm missing that I should have included? atelfo.github.io/2022/03/19/the…

one of the most insidious mistakes in biology is "mistaking the map for the territory". we conflate biological maps (the genome, transcriptome, etc) with underlying biological reality. we are tricked into thinking our tools give us a complete picture. using AI to analyze

#biotech old timers should not ignore this trend….be open to new models. Times are always changing adapt or become extinct. biopharmadive.com/news/biotech-s…

Great to see friends called out like Guillermo Vela and Michael Retchin. As a founder myself, I certainly echo the sentiment of room for both. I’d love to see more seed funds step up and really help build versus the “come back to us when you have more data” which to be honest

$50 billion a year is spent on failed cancer drug development by the pharma industry. Our new paper is a case study on what goes wrong. Consilium Scientific @Jhickmana jamanetwork.com/journals/jaman…

Hi All, our Texas-based cancer-focused accelerator is recruiting for next year. Link to apply is below. It’s a very simple application. If you’re a company or PI with an interest is developing yourself or your projects into investable entities you’re a fit!

Hola San Antonio! Know any teens interested in journalism? Please share the word about this great program led by some amazing professionals. 👇🏽

Identifying targets is the backbone of drug discovery. @svsaraf and I wrote an article about the current state and future opportunities in target id+validation for the Bits in Bio blog! Link in bio ⬆️

In oncology, it’s common to hear, “We need better therapies.” That’s true. But, given oncology’s unyielding 95% clinical failure rate, the clear conclusion should be that we first need better theories about cancer. There’s nothing different in having a different target

before recursion and exscientia, there was Schrödinger - founded in 1990, it's the OG AI-driven drug discovery company. on this episode of the KdT Ventures podcast, Mack Healy and I dive into the science and business of a juggernaut of biopharma R&D software. we discuss: -

Can we save the koalas with biotech? 🐨 Have also been thinking about opportunities in biodesign and SOTA omics software. Check out new theses below -

The uninformed perception is that biotech success can be easy. Find a great drug, run a trial with a great result, get bought out! Join me on a thread that explores the Bellus journey and how hard the path to drug development success can really be. $BLU $XBI

A little over a year ago, I wrote about how platform biotech is going through a recalibration phase 🧬 This recalibration phase has primarily been based on increasing predictive validity over the number/size of the screens, increasing chemical space, and directly focusing on

JPM Healthcare is in a week. Although this is an investment conference, it’s also the highest number of biotech events per square mile anywhere in the world—more parties than your bioRxiv-addled brain can comprehend. So the TechBio Transformers community has crowdsourced events in a single

How to detect BS in biotech PR — useful airplane reading if you’re heading to JPM. pharmagellan.com/blog/red-flags…